TIGIT and head and neck squamous cell carcinoma: For instance, in the model of the head and neck squamous cell carcinoma, anti-PD-L1 treatment in vivo resulted in increased CD155 expression on MDSCs and, interestingly, vice versa, the blockade of TIGIT resulted in the upregulation of PD-L1 expression [25].